Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 51, 2017 - Issue 5
Journal homepage
1,234
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Outpatient photodynamic-guided diagnosis of carcinoma in situ with flexible cystoscopy: an alternative to conventional inpatient photodynamic-guided bladder biopsies in the operating theatre?

Karin MogensenDepartment of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; View further author information
,
Anders GlenthøjDepartment of Pathology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; View further author information
,
Birgitte Grønkær ToftDepartment of Pathology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; View further author information
,
Thomas ScheikeDepartment of Biostatistics, University of Copenhagen, Copenhagen, DenmarkView further author information
&
Gregers Gautier HermannDepartment of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Correspondence[email protected]
View further author information
Pages 376-380 | Received 23 Mar 2017, Accepted 02 Jul 2017, Published online: 26 Jul 2017

References

  • van Gils-Gielen RJ, Witjes WP, Caris CT, et al. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology. 1995;45:581–586.
  • Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992;19:499–508.
  • Sylvester RJ, van der MA, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005;66(6 Suppl 1):90–107.
  • Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.
  • Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021–1029.
  • Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer. 2016;2:27–36.
  • Hungerhuber E, Stepp H, Kriegmair M, et al. Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology. 2007;69:260–264.
  • Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64:846–854.
  • Wong KA, Zisengwe G, Athanasiou T, et al. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int. 2013;112:561–567.
  • Hermann GG, Mogensen K, Toft BG, et al. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol. 2012;46:31–36.
  • Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865–877.
  • WHO. WHO classification of tumours. Pathology & genetics. Tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
  • Mogensen K, Christensen KB, Vrang ML, et al. Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol. 2016;50:170–174.
  • van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005;47:736–748.
  • Haase RN, Harving N. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ? Scand J Urol. 2015;49:338–340.
  • Swietek N, Waldert M, Rom M, et al. The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature. J Urol. 2012;188:748–753.
  • Kaasinen E, Wijkstrom H, Rintala E, et al. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scand J Urol. 2016;50:360–368.
  • Grimbergen MC, van Swol CF, Jonges TG, et al. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol. 2003;44:51–56.
  • Draga RO, Grimbergen MC, Kok ET, et al. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. Eur Urol. 2010;57:655–660.
  • Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int. 2010;105:789–794.
  • Loidl W, Schmidbauer J, Susani M, et al. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol. 2005;47:323–326.
  • Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178:62–67.
  • Lindvold LR, Hermann GG. An optical method for reducing green fluorescence from urine during fluorescence-guided cystoscopy. Methods Appl Fluoresc. 2016;4:045002.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.